Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 23, Number 5—May 2017
Research Letter

ESBL- and Carbapenemase-Producing Enterobacteriaceae in Patients with Bacteremia, Yangon, Myanmar, 2014

Tin O. MyatComments to Author , Rachel F. Hannaway, Khwar N. Zin, Wah W. Htike, Kyu K. Win, John A. Crump, David R. Murdoch, and James E. Ussher1
Author affiliations: University of Medicine 1, Yangon, Myanmar (T.O. Myat, W.W. Htike, K.K. Win); University of Otago, Dunedin, New Zealand (R.F. Hannaway, J.A. Crump, J.E. Ussher); Yangon General Hospital, Yangon (K.N. Zin); University of Otago, Christchurch, New Zealand (D.R. Murdoch); Southern Community Laboratories, Dunedin Hospital, Dunedin (J.E. Ussher)

Main Article

Table

Antimicrobial drug susceptibility of Enterobacteriaceae and Acinetobacter spp. isolated from blood cultures of inpatients from 3 hospitals in Yangon, Myanmar, 2014*

 Organism, no. (%) susceptible
Agent
 Escherichia coli, n = 20
 Klebsiella pneumoniae, n = 7
 Salmonella enterica, n = 6
 Enterobacter cloacae, n = 1
 Acinetobacter spp., n = 3
Ampicillin
 2 (10)
 0
 6 (100)
 0
 NT
Amoxicillin/clavulanic acid
 5 (25)
 1 (14)
 6 (100)
 0
 NT
Piperacillin/tazobactam
 13 (65)
 2 (29)
 6 (100)
 0
 2 (67)
Cefuroxime
 5 (25)
 1 (14)
 NT
 0
 NT
Ceftriaxone
 6 (30)
 1 (14)
 6 (100)
 0
 1 (33)
Ceftazidime
 6 (30)
 1 (14)
 6 (100)
 0
 0
Cefipime
 7 (35)
 1 (14)
 6 (100)
 0
 2 (67)
Cefoxitin
 11 (55)
 4 (57)
 NT
 0
 NT
Aztreonam
 6 (30)
 1 (14)
 6 (100)
 0
 NT
Ertapenem
 17 (85)
 4 (57)
 6 (100)
 1 (100)
 NT
Imipenem
 17 (85)
 4 (57)
 6 (100)
 1 (100)
 3 (100)
Meropenem
 17 (85)
 4 (57)
 6 (100)
 1 (100)
 3 (100)
Gentamicin
 14 (70)
 2 (29)
 NT
 1 (100)
 2 (67)
Tobramycin
 9 (45)
 1 (14)
 NT
 0
 3 (100)
Ciprofloxacin
 1 (5)
 1 (14)
 3 (43)
 0
 2 (67)
Chloramphenicol
 11 (55)
 2 (29)
 6 (100)
 0
 NT
Colistin†
 20 (100)
 7 (100)
 6 (100)
 1 (100)
 3 (100)
Nitrofurantoin
 16 (80)
 1 (14)
 NT
 0
 NT
Trimethoprim/ sulfamethoxazole 2 (10) 2 (29) 6 (100) 0 2 (67)

*NT, not tested.
†Because there are no Clinical and Laboratory Standards Institute for susceptibility testing criteria for colistin for Enterobaceriaceae, European Committee on Antimicrobial Susceptibility Testing (EUCAST) criteria were used (susceptible if MIC <2 mg/L, per EUCAST criteria version 6.0, 2016; http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_6.0_Breakpoint_table.pdf).

Main Article

1All authors contributed equally to this article.

Page created: April 14, 2017
Page updated: April 14, 2017
Page reviewed: April 14, 2017
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external